|
|
Post by mockingjay on Jan 8, 2016 13:24:12 GMT -5
An internal memo from Sanofi .
Dear Colleagues:
We wanted to infrom you that Sanofi has excercised the right to terminate its agreement with Mannkind Corporation, the developer of Afrezza inhalted insulin, and will transfer back the rights of Afrezza to Mannkind as of April 4, 2016.
Despite substantial efforts leading to hig levels of brand awareness with key diabetes-treating healthcare professionals, Afrezza has continued to demontrate low volume and revenue performance in the marketplkace
We will continue to promote Afrezza in the U.S. as planned until April 4, 2016, and will fulfill orders for a certain period thereafter. We are working with Mannkind on a smooth transition and will provide you with an update once we have more information.
We would like to acknowledge the efforts of the extended team who helped launch Afrezza in the U.S. and thank them for all of their dedication, which will be important through the next several months as we continue our support for Afrezza and then transition the product back to Mannkind.
We remain focused on helping meet the needs of people living with diabetes with our current offerings and on the continued expansion of our portfolio.
It is important to remember that all media inquiries need to be managed by our U.S. media remations team, so please send to usmediarelations@sanofi.com.
We will be sure to keep you posted on any additional updates
Regards
Jez Moulding (Sanofi US Country Chair)
Andrew Purcell (U.S. Diabetes Lead)
|
|
|
|
Post by hawaiiguy42 on Jan 8, 2016 13:29:06 GMT -5
An internal memo from Sanofi . Dear Colleagues: We wanted to infrom you that Sanofi has excercised the right to terminate its agreement with Mannkind Corporation, the developer of Afrezza inhalted insulin, and will transfer back the rights of Afrezza to Mannkind as of April 4, 2016. Despite substantial efforts leading to hig levels of brand awareness with key diabetes-treating healthcare professionals, Afrezza has continued to demontrate low volume and revenue performance in the marketplkace We will continue to promote Afrezza in the U.S. as planned until April 4, 2016, and will fulfill orders for a certain period thereafter. We are working with Mannkind on a smooth transition and will provide you with an update once we have more information. We would like to acknowledge the efforts of the extended team who helped launch Afrezza in the U.S. and thank them for all of their dedication, which will be important through the next several months as we continue our support for Afrezza and then transition the product back to Mannkind. We remain focused on helping meet the needs of people living with diabetes with our current offerings and on the continued expansion of our portfolio. It is important to remember that all media inquiries need to be managed by our U.S. media remations team, so please send to usmediarelations@sanofi.com. We will be sure to keep you posted on any additional updates Regards Jez Moulding (Sanofi US Country Chair) Andrew Purcell (U.S. Diabetes Lead) What a crock of Bull-KaKa... it's called CYA and nothing more! |
|
|
|
Post by hawaiiguy42 on Jan 8, 2016 13:29:45 GMT -5
Thanks for posting.
|
|
rey
Newbie
Posts: 12 
|
Post by rey on Jan 8, 2016 13:52:41 GMT -5
You got me in Bull-KAKA  |
|
|
|
Post by od on Jan 8, 2016 13:58:54 GMT -5
An internal memo from Sanofi . Dear Colleagues: We wanted to infrom you that Sanofi has excercised the right to terminate its agreement with Mannkind Corporation, the developer of Afrezza inhalted insulin, and will transfer back the rights of Afrezza to Mannkind as of April 4, 2016. Despite substantial efforts leading to hig levels of brand awareness with key diabetes-treating healthcare professionals, Afrezza has continued to demontrate low volume and revenue performance in the marketplkace We will continue to promote Afrezza in the U.S. as planned until April 4, 2016, and will fulfill orders for a certain period thereafter. We are working with Mannkind on a smooth transition and will provide you with an update once we have more information. We would like to acknowledge the efforts of the extended team who helped launch Afrezza in the U.S. and thank them for all of their dedication, which will be important through the next several months as we continue our support for Afrezza and then transition the product back to Mannkind. We remain focused on helping meet the needs of people living with diabetes with our current offerings and on the continued expansion of our portfolio. It is important to remember that all media inquiries need to be managed by our U.S. media remations team, so please send to usmediarelations@sanofi.com. We will be sure to keep you posted on any additional updates Regards Jez Moulding (Sanofi US Country Chair) Andrew Purcell (U.S. Diabetes Lead) What a crock of Bull-KaKa... it's called CYA and nothing more! Whether or not I agree with your assessment, who do Jez and Andrew need 'cover' from? They did not in-license Afrezza. (If they are on the hot-seat, this letter does nothing.) |
|
|
|
Post by bradleysbest on Jan 8, 2016 14:25:45 GMT -5
Would like to know how much money was spent on DTC & if commercials were in the near future?
|
|
|
|
Post by mockingjay on Jan 8, 2016 16:33:36 GMT -5
An internal memo from Sanofi . Dear Colleagues: We wanted to infrom you that Sanofi has excercised the right to terminate its agreement with Mannkind Corporation, the developer of Afrezza inhalted insulin, and will transfer back the rights of Afrezza to Mannkind as of April 4, 2016. Despite substantial efforts leading to hig levels of brand awareness with key diabetes-treating healthcare professionals, Afrezza has continued to demontrate low volume and revenue performance in the marketplkace We will continue to promote Afrezza in the U.S. as planned until April 4, 2016, and will fulfill orders for a certain period thereafter. We are working with Mannkind on a smooth transition and will provide you with an update once we have more information. We would like to acknowledge the efforts of the extended team who helped launch Afrezza in the U.S. and thank them for all of their dedication, which will be important through the next several months as we continue our support for Afrezza and then transition the product back to Mannkind. We remain focused on helping meet the needs of people living with diabetes with our current offerings and on the continued expansion of our portfolio. It is important to remember that all media inquiries need to be managed by our U.S. media remations team, so please send to usmediarelations@sanofi.com. We will be sure to keep you posted on any additional updates Regards Jez Moulding (Sanofi US Country Chair) Andrew Purcell (U.S. Diabetes Lead) Sorry I type so fast, don't know how to include the picture in this post , so I type this memo myself: Dear Colleagues: We wanted to inform you that Sanofi has excercised the right to terminate its agreement with Mannkind Corporation, the developer of Afrezza inhaled insulin, and will transfer back the rights of Afrezza to Mannkind as of April 4, 2016. Despite substantial efforts leading to high levels of brand awareness with key diabetes-treating healthcare professionals, Afrezza has continued to demontrate low volume and revenue performance in the marketplace. We will continue to promote Afrezza in the U.S. as planned until April 4, 2016, and will fulfill orders for a certain period thereafter. We are working with Mannkind on a smooth transition and will provide you with an update once we have more information. We would like to acknowledge the efforts of the extended team who helped launch Afrezza in the U.S. and thank them for all of their dedication, which will be important through the next several months as we continue our support for Afrezza and then transition the product back to Mannkind. We remain focused on helping meet the needs of people living with diabetes with our current offerings and on the continued expansion of our portfolio. It is important to remember that all media inquiries need to be managed by our U.S. media remations team, so please send to usmediarelations@sanofi.com. We will be sure to keep you posted on any additional updates Regards Jez Moulding (Sanofi US Country Chair) Andrew Purcell (U.S. Diabetes Lead) |
|
|
|
Post by mockingjay on Jan 8, 2016 16:41:13 GMT -5
sorry for my typing mistake from the original memo (I cannot cut/paste from this one)
|
|
